Your browser doesn't support javascript.
loading
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Schjesvold, Fredrik H; Dimopoulos, Meletios-Athanasios; Delimpasi, Sosana; Robak, Pawel; Coriu, Daniel; Legiec, Wojciech; Pour, Ludek; Spicka, Ivan; Masszi, Tamas; Doronin, Vadim; Minarik, Jiri; Salogub, Galina; Alekseeva, Yulia; Lazzaro, Antonio; Maisnar, Vladimir; Mikala, Gábor; Rosiñol, Laura; Liberati, Anna Marina; Symeonidis, Argiris; Moody, Victoria; Thuresson, Marcus; Byrne, Catriona; Harmenberg, Johan; Bakker, Nicolaas A; Hájek, Roman; Mateos, Maria-Victoria; Richardson, Paul G; Sonneveld, Pieter.
Afiliação
  • Schjesvold FH; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway. Electronic address: fredrikschjesvold@gmail.com.
  • Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
  • Delimpasi S; Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece.
  • Robak P; Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland.
  • Coriu D; Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania.
  • Legiec W; Department of Hematology and Bone Marrow Transplantation, St John of Dukla Oncology Center of Lublin, Lublin, Poland.
  • Pour L; Department of Internal Medicine, University Hospital Brno, Brno, Czech Republic.
  • Spicka I; Charles University and General Hospital, Prague, Czech Republic.
  • Masszi T; Department of Hematology, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
  • Doronin V; Hematology Department, State Budget Healthcare Institution of Moscow, City Clinical Hospital #40 of Moscow Healthcare Department, Moscow, Russia.
  • Minarik J; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic; University Hospital Olomouc, Olomouc, Czech Republic.
  • Salogub G; Chemotherapy of Oncohematology Diseases and Bone Marrow Transplantation Department, Almazov National Medical Research Centre, Ministry of Health of Russia, St Petersburg, Russia.
  • Alekseeva Y; Chemotherapy of Oncohematology Diseases and Bone Marrow Transplantation Department, Almazov National Medical Research Centre, Ministry of Health of Russia, St Petersburg, Russia.
  • Lazzaro A; Division of Hematology and Bone Marrow Transplant Center, Hospital Guglielmo da Saliceto, Piacenza, Italy.
  • Maisnar V; 4th Department of Medicine - Haematology, Charles University Hospital, Hradec Králové, Czech Republic.
  • Mikala G; South-Pest Central Hospital, National Institute for Hematology and Infectious Diseases, Budapest, Hungary.
  • Rosiñol L; Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, IDIBAPS, Josep Carreras Research Institute, Hospital Clinic Provincial, Barcelona, Spain.
  • Liberati AM; Università degli Studi di Perugia, Azienda Ospedaliera Santa Maria di Terni, Terni, Italy.
  • Symeonidis A; Department of Hematology, University of Patras, Patras, Greece.
  • Moody V; Oncopeptides AB, Stockholm, Sweden.
  • Thuresson M; Oncopeptides AB, Stockholm, Sweden.
  • Byrne C; Oncopeptides AB, Stockholm, Sweden.
  • Harmenberg J; Oncopeptides AB, Stockholm, Sweden.
  • Bakker NA; Oncopeptides AB, Stockholm, Sweden.
  • Hájek R; Department of Hemato-oncology, University Hospital Ostrava, Ostrava, Czech Republic; Department of Hemato-oncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  • Mateos MV; Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain.
  • Richardson PG; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Lancet Haematol ; 9(2): e98-e110, 2022 Feb.
Article em En | MEDLINE | ID: mdl-35032434
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiplo Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Haematol Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiplo Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Haematol Ano de publicação: 2022 Tipo de documento: Article